Clinical trials: Hepatic Tumors
Hepatocellular Carcinoma
OREIOS International Study
Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care.
- Trial name
- OREIOS (NCT05239507)
- Where
- 21 sites in Brazil, Egypt and 9 more
- Volunteers
- 1,127 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Study of PTS100 in Primary HCC Patients
This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local…
- Trial name
- OASES (NCT03447951)
- Testing
- Para-Toluenesulfonamide
- Where
- 3 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Gongwin Biopharm Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams…
- Trial name
- NCT04953910
- Testing
- ASTX727
- Where
- 22 sites in United States, Armenia and 6 more
- Volunteers
- 27 people
- Sponsor
- Taiho Oncology, Inc.
Primary Hepatocellular Carcinoma
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.
- Trial name
- NCT00966251
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- CureTech Ltd
Hepatocellular Carcinoma
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and…
- Trial name
- NCT05440708
- Testing
- TTI-101, Pembrolizumab, Atezolizumab
- Where
- 21 sites in United States
- Volunteers
- 193 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Hepatic Impairment, Healthy Volunteers
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic…
- Trial name
- NCT06535399
- Testing
- BMS-986369
- Where
- 3 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Celgene
Hepatocellular Carcinoma
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made.
- Trial name
- STELLA (NCT01539681)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Italy
- Volunteers
- 234 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular, Hepatoma
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC).
- Trial name
- NCT00503867
- Testing
- SIR-Spheres microspheres
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sirtex Medical
Carcinoma, Hepatocellular
Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
This study investigates the safety and efficacy of the combination therapy with BAY86-9766 and sorafenib in patients with liver cancer. Safety will be determined by laboratory and other evaluations.
- Trial name
- BASIL (NCT01204177)
- Testing
- BAY86-9766 MEK Inhibitor + Sorafenib
- Where
- 15 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 70 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
- Trial name
- NCT05320692
- Testing
- TACE+Camrelizumab+Apatinib mesylate, TACE
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
The purpose of this study is to determine whether patients with hepatocellular carcinoma who receive either E7050 administered with Sorafenib or Sorafenib alone experience greater benefit (cancer responds to treatment) when E7050…
- Trial name
- NCT01271504
- Testing
- Sorafenib
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 102 people
- Sponsor
- Eisai Inc.
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths.
- Trial name
- NCT06858813
- Testing
- Lenvatinib, ABBV-324
- Where
- 22 sites in United States, China and 5 more
- Volunteers
- 232 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07713290
- Testing
- GKL-006 Injection, Transarterial chemoembolization (TACE)
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Liver Cancer
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
This is a prospective, multicenter, randomized, parallel-controlled, non-inferiority clinical trial that will be conducted at multiple clinical trial institutions in China.
- Trial name
- NCT07356531
- Testing
- Transcatheter Arterial Chemoembolization
- Where
- 15 sites in China
- Volunteers
- 216 people
- Sponsor
- JIANGSU SHENMING Medical Technology CO., Ltd
Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types.
- Conditions
- Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT06034860
- Testing
- MT-8421, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Molecular Templates, Inc.
Hepatocellular Cancer, Liver Cancer
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with sorafenib. OMP-54F28 will be administered IV on Day 1 of each 21-day cycle.
- Trial name
- NCT02069145
- Testing
- OMP-54F28 with Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Hepatocellular Carcinoma (HCC)
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU…
- Trial name
- NCT02508467
- Testing
- Fisogatinib (BLU-554)
- Where
- 41 sites in United States, China and 10 more
- Volunteers
- 146 people
- Sponsor
- Blueprint Medicines Corporation
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Brazilian Reality of Hepatocellular Carcinoma
National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage, Hepatocellular Carcinoma Stage I, Hepatocellular Carcinoma Stage II
- Trial name
- BRA-HEP (NCT06230328)
- Where
- 11 sites in Brazil
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Hepatic Insufficiency
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of single oral doses of Alisporivir in subjects with mild and moderate hepatic impairment compared to matched healthy subjects with normal…
- Trial name
- NCT01860326
- Testing
- Alisporivir
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA
Hepatocellular Carcinoma
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in…
- Trial name
- SAFE-T-HBV (NCT04745403)
- Testing
- mRNA HBV/TCR T-cells
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.